Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Immunogenic Cell Death (Icd)-Inducers in Non-Small-Cell Lung Carcinoma (Nsclc): Current Knowledge and Future Perspective Publisher Pubmed



Kashefizadeh A1 ; Kazemizadeh H2
Authors

Source: Clinical and Translational Oncology Published:2023


Abstract

The prevalence of non-small-cell lung cancer (NSCLC) is rising every year all around the world. The interaction between cancer cells and the tumor microenvironment (TME) is a crucial factor in determining the development of human neoplasms. Organellar and cellular stress are induced during immunogenic cell death (ICD), a particularly functional response pattern. ICD is a separate but poorly characterized entity caused by various cancer treatments. The induction of ICD has the potential to change TME and the recruitment of tumor-infiltrating lymphocytes (TILs), and the coupling of ICD-inducers and other therapeutic approaches can have a synergistic role in boosting anticancer impacts. The purpose of this study is to review the studies in the field of NSCLC using ICD-inducers as a treatment strategy or as a combination therapy. This review provide for researches a better view of what has been done so far and the challenges they face in the future. © 2022, The Author(s), under exclusive licence to Federacion de Sociedades Espanolas de Oncologia (FESEO).
Other Related Docs
6. Crispr-Cas9-Mediated Gene Therapy in Lung Cancer, Clinical and Translational Oncology (2023)
9. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
18. Combination Therapy, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)